Merck & Co., Inc. (MRK)
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Here's Why Merck (MRK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Merck Has Many Bullish Attributes (Technical Analysis)
Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, momentum indicators are bullish, and volume shows institutional accumulation. Since its May low, the company has outperformed the S&P 500, with relative strength now trending higher and above its 30-week EMA.
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases, including ADP, Roper Technologies, Atmos, and Snap-on. Other notable companies expecting dividend hikes include Motorola Solutions, McCormick, and Raymond James, each with robust earnings trends.
Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript
Merck & Co., Inc. ( MRK ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michelle Kehily Conference Call Participants Elena Meng Michael Paas Stephen S. Morse Magdalena Sobieszczyk Presentation Unknown Attendee So our final panel of the day is about vaccines.
Here's Why Merck (MRK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Merck & Co., Inc. ( MRK ) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck Research Laboratories Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health Conference Call Participants Taylor Hanley - JPMorgan Chase & Co, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Vamil Divan - Guggenheim Securities, LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
